First nirmatrelvir + ritonavir generic prequalified
M
WHO Prequalification Unit (PQT) added the below new product to its prequalified list:
News
Variation application form and FAQ Variation document updated
M
WHO Prequalification Team – Medicines (PQT/MED) updated the variation application form and FAQ variation document:
PRESENTATIONS NOW AVAILABLE - Joint UNICEF-UNFPA-WHO Meeting with Manufacturers and Suppliers
ID
IVD
IS
M
V
VCP
The 2022 Joint UNICEF-UNFPA-WHO Meeting with Manufacturers and Suppliers took place from 28 November to 1 December 2022 at UN City, Marmorvej 51, 2100 Copenhagen,
HLL Lifecare’s ethinylestradiol/levonorgestrel prequalified
M
WHO Prequalification Unit (PQT) added the below new product to its prequalified list:
Lupin’s dolutegravir/lamivudine/tenofovir prequalified
M
WHO Prequalification Unit (PQT) added the below new product to its prequalified list:
Newly prequalified Active Pharmaceutical Ingredient (API)
M
Aabcavir (sulfate) (WHOAPI-377) manufactured by Jiangsu Weiqida Pharmaceutical Co Ltd, has been prequalified by the WHO Prequalific
First delamanid prequalified
M
WHO Prequalification Unit (PQT) added the below new product to its prequalified list:
Desano’s efavirenz/lamivudine/tenofovir tablet prequalified
M
WHO Prequalification Unit (PQT) added the below new product to its prequalified list:
First paediatric linezolid prequalified
M
WHO Prequalification Unit (PQT) added the below new product to its prequalified list:
Independent Performance Evaluation for SARS-COV-2 Antigen RDTS
IVD
WHO PQT in collaboration with PATH and FIND will perform an independent performance evaluation to generate additional performance data for RDTs that are undergoing EUL assessment and for those that
Macleods’ Pyrimethamine/Sulfadoxine + Amodiaquine (hydrochloride) dispersible tablets prequalified
M
WHO Prequalification Unit (PQT) added the below new product to its prequalified list:
New Invitation for Expression of Interest (EOI) for Active Pharmaceutical Ingredients (APIs) published
M
New Invitation for Expression of Interest (EOI) for Active Pharmaceutical Ingredients (APIs) published
The following APIs were added:
New Invitation for Expression of Interest (EOI) to manufacturers and suppliers of medicinal products for treatment of hepatitis B and C published
M
New Invitation for Expression of Interest (EOI) to manufacturers and suppliers of medicinal products for treatment of hepatitis B and C.
Newly prequalified Active Pharmaceutical Ingredient (API)
M
Molnupiravir (WHOAPI-439) manufactured by Emcure Pharmaceuticals Ltd, has been prequalified by the WHO Prequalification Unit - Medicines Team (PQT/MED) u